Total Payments
$410,364
2024 Payments
$84,815
Companies
19
Transactions
421
Medicare Patients
598
Medicare Billing
$147,615
Payment Breakdown by Category
Consulting$277,314 (67.6%)
Other$64,165 (15.6%)
Travel$44,933 (10.9%)
Research$16,578 (4.0%)
Food & Beverage$7,375 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $277,314 | 180 | 67.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $60,435 | 20 | 14.7% |
| Travel and Lodging | $44,933 | 73 | 10.9% |
| Unspecified | $16,578 | 35 | 4.0% |
| Food and Beverage | $7,375 | 112 | 1.8% |
| Honoraria | $3,730 | 1 | 0.9% |
Payments by Type
General
$393,786
386 transactions
Research
$16,578
35 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $170,867 | 124 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $54,338 | 44 | $0 (2018) |
| Actelion Pharmaceuticals US, Inc. | $52,787 | 89 | $0 (2024) |
| Actelion Pharmaceuticals, Ltd | $42,047 | 37 | $0 (2022) |
| United Therapeutics Corporation | $40,095 | 64 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $11,600 | 3 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $8,514 | 12 | $0 (2023) |
| Edwards Lifesciences Corporation | $7,083 | 9 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $5,776 | 8 | $0 (2017) |
| Merck Sharp & Dohme LLC | $5,008 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $84,815 | 64 | Boston Scientific Corporation ($54,120) |
| 2023 | $48,509 | 66 | Boston Scientific Corporation ($29,780) |
| 2022 | $36,661 | 27 | Actelion Pharmaceuticals, Ltd ($20,215) |
| 2021 | $5,731 | 11 | United Therapeutics Corporation ($3,010) |
| 2020 | $30,401 | 18 | Boston Scientific Corporation ($22,359) |
| 2019 | $80,164 | 86 | Boston Scientific Corporation ($29,800) |
| 2018 | $88,180 | 99 | Novartis Pharmaceuticals Corporation ($37,747) |
| 2017 | $35,902 | 50 | Novartis Pharmaceuticals Corporation ($16,591) |
All Payment Transactions
421 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | United Therapeutics Corporation | — | — | Cash or cash equivalent | $137.50 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION | ||||||
| 12/24/2024 | United Therapeutics Corporation | — | — | Cash or cash equivalent | $137.50 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION | ||||||
| 12/19/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| Category: Clinical Trial Product_CRM | ||||||
| 12/19/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $385.00 | General |
| Category: Clinical Trial Product_CRM | ||||||
| 12/19/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $100.00 | General |
| Category: Clinical Trial Product_CRM | ||||||
| 12/15/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 12/02/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $4,300.00 | General |
| Category: Clinical Trial Product_CRM | ||||||
| 12/02/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $385.00 | General |
| Category: Clinical Trial Product_CRM | ||||||
| 12/02/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $100.00 | General |
| Category: Clinical Trial Product_CRM | ||||||
| 11/13/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Consulting Fee | Cash or cash equivalent | $6,750.00 | General |
| Category: Cardiology | ||||||
| 11/11/2024 | KAMADA LTD. | CYTOGAM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,060.00 | General |
| Category: Infectious Disease | ||||||
| 11/01/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Consulting Fee | Cash or cash equivalent | $2,670.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/30/2024 | United Therapeutics Corporation | — | — | Cash or cash equivalent | $687.50 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION | ||||||
| 10/29/2024 | KAMADA LTD. | CYTOGAM (Drug) | Food and Beverage | Cash or cash equivalent | $98.86 | General |
| Category: Infectious Disease | ||||||
| 10/29/2024 | KAMADA LTD. | CYTOGAM (Drug) | Food and Beverage | Cash or cash equivalent | $60.58 | General |
| Category: Infectious Disease | ||||||
| 10/24/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| Category: Clinical Trial Product_CRM | ||||||
| 10/24/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $385.00 | General |
| Category: Clinical Trial Product_CRM | ||||||
| 10/24/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $100.00 | General |
| Category: Clinical Trial Product_CRM | ||||||
| 10/03/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Travel and Lodging | In-kind items and services | $322.94 | General |
| Category: Cardiology | ||||||
| 10/03/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Cardiology | ||||||
| 10/03/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Cardiology | ||||||
| 10/03/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Cardiology | ||||||
| 10/03/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Cardiology | ||||||
| 09/24/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Travel and Lodging | In-kind items and services | $487.10 | General |
| Category: Cardiology | ||||||
| 09/20/2024 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $125.47 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL EXTENSION STUDY OF APD811 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION | United Therapeutics Corporation | $9,232 | 18 |
| AC-055-205 | Actelion Pharmaceuticals, Ltd | $4,896 | 10 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION | United Therapeutics Corporation | $1,523 | 5 |
| An open-label extension study of APD811-003 in Patients with Pulmonary Arterial Hypertension | United Therapeutics Corporation | $541.67 | 1 |
| An Open-label Extension Study of Ralinepag in Patients With Pulmonary Arterial Hypertension | United Therapeutics Corporation | $385.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 175 | 439 | $275,391 | $46,604 |
| 2022 | 4 | 132 | 316 | $203,436 | $32,186 |
| 2021 | 5 | 162 | 387 | $214,284 | $32,495 |
| 2020 | 3 | 129 | 460 | $250,366 | $36,330 |
Total Patients
598
Total Services
1,602
Medicare Billing
$147,615
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 71 | 164 | $126,772 | $20,005 | 15.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 38 | 183 | $100,833 | $19,363 | 19.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 23 | 23 | $24,955 | $3,731 | 15.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $13,871 | $2,034 | 14.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 30 | 56 | $8,960 | $1,471 | 16.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 71 | 149 | $115,177 | $17,801 | 15.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 129 | $71,079 | $11,716 | 16.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 12 | 12 | $13,020 | $1,960 | 15.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 19 | 26 | $4,160 | $709.73 | 17.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 70 | 126 | $97,398 | $15,448 | 15.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 23 | 96 | $52,296 | $8,865 | 17.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 26 | 26 | $28,210 | $3,686 | 13.1% |
| 93750 | Evaluation of lower heart chamber assist device with physician analysis | Facility | 2021 | 18 | 101 | $30,300 | $3,423 | 11.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 25 | 38 | $6,080 | $1,073 | 17.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 28 | 166 | $88,312 | $15,591 | 17.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 88 | 158 | $122,134 | $14,814 | 12.1% |
| 93750 | Evaluation of lower heart chamber assist device with physician analysis | Facility | 2020 | 13 | 136 | $39,920 | $5,925 | 14.8% |
About Dr. Teresa De Marco, MD
Dr. Teresa De Marco, MD is a Internal Medicine healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1669420956.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Teresa De Marco, MD has received a total of $410,364 in payments from pharmaceutical and medical device companies, with $84,815 received in 2024. These payments were reported across 421 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($277,314).
As a Medicare-enrolled provider, De Marco has provided services to 598 Medicare beneficiaries, totaling 1,602 services with total Medicare billing of $147,615. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Cardiovascular Disease, Advanced Heart Failure and Transplant Cardiology
- Location San Francisco, CA
- Active Since 05/05/2006
- Last Updated 10/12/2017
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1669420956
Products in Payments
- CLINICAL TRIAL PRODUCT (Device) $76,749
- ENTRESTO (Drug) $54,338
- UPTRAVI (Drug) $16,705
- NONE (Drug) $13,524
- Clinical Trial Product (Device) $10,218
- TYVASO (Drug) $10,007
- XARELTO (Drug) $5,776
- WINREVAIR (Biological) $4,895
- OPSUMIT MACITENTAN (Drug) $4,882
- CYTOGAM (Drug) $3,877
- OPSUMIT (Drug) $3,679
- BOSENTAN (Drug) $1,126
- CardioMEMS HF System (Device) $766.00
- HeartMate 3 Left Ventricular Assist Device (Device) $503.71
- HeartMate 3 Left Ventricular Dev (Device) $297.61
- Circulatory Support (Device) $133.98
- HeartWare HVAD (Device) $125.79
- REMODULIN (Drug) $88.14
- Paragonix SherpaPak Cardiac Transport System (Device) $40.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Francisco
Dr. Fred Cohen, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
John Teerlink, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Kenneth Binmoeller, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. Hope Rugo, Md, MD
Internal Medicine — Payments: $881,117
Internal Medicine $881,117
Dr. Steven Harris, M.d, M.D
Internal Medicine — Payments: $806,637
Internal Medicine $806,637
Dr. Kenneth Colley, Md, MD
Internal Medicine — Payments: $732,736
Internal Medicine $732,736